Infektionsmedizin und Zoonosen
print

Links und Funktionen

Navigationspfad


Inhaltsbereich

Ausgewählte Vorträge

2016

  • "Development of recombinant MVA-MERS-S for Phase I Clinical Evaluation: A candidate Vaccine against Middle East Respiratory Syndrome Coronavirus.", A. Volz, 35th Annual Meeting of the American Society for Virology, Blacksburg, Virginia, USA, 17.-22.06.2016
  • "Development of MVA-MERS-S: A candidate vaccine for humans and camels.", G. Sutter, Leibniz Center Infection Symposium 2016 "Vaccines", Bernhard Nocht Institute, Hamburg, 28.-29.01.2016

2015

  • "Recombinant vaccinia MVA expressing E and prM/M proteins of West Nile Virus for vaccine generation.", A. Volz, 25 th Annual Meeting of the Society for Virology, Bochum, 18.-21.03.2015
  • "Modified Vaccinia virus Ankara induced rapid recruitment of neutrophils into the lung requires complement component C5.", M.H. Lehmann, 25 th Annual Meeting of the Society for Virology, Bochum, 18.-21.03.2015
  • "Rekombinantes Vacciniavirus MVA zur schnellen Impfstoffentwicklung gegen West Nil Fieber, MERS und Ebola.", A. Volz, 9. Internationaler Kongress "Forum Life Science", Technische Universität München, Garching, 11.-12.03.2015

2014

  • "Middle east respiratory  syndrome Coronavirus spike protein delivered by modified Vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.", G. Sutter, XX International Poxvirus, Asfarvirus & Iridovirus Conference, Victoria BC, Canada, 26.09.-30.09.2014
  • "Das Porcine Circovirus 2 - ein ubiquitär vorkommendes Virus neu entdeckt!", R. Fux, 33. Jahrestagung der DVG-Fachgruppe "AVID", Kloster Banz, Bad Staffelstein, 17.09.-19.09.2014

2013

  • "Modified Vaccinia virus Ankara vectors for antigen delivery - from (pre)clinical evaluation to process development.", G. Sutter, 3rd Workshop European Network on Viral Vaccine Processes, Dechema - Haus, Frankfurt a.M., 25.11.-26.11.2013
  • "Low dose immunization with Modified Vaccinia virus Ankara induces rapid in vivo expansion of protective CD8+T Cells.", A. Volz, Medical Biodefense Conference 2013, Munich, 22.-25.10.2013
  • "Pitfalls of BVD Eradication.", R. Fux, Cattle Association of Veterinary Ireland, Galway, Irland, 11.-12.10.2013
  • "Harzardous Orthopoxviruses: Pathogenesis of infection, prevention and treatment.", G. Sutter, NATO Bio Warfare Defence Awareness Course, NATO School, Oberammergau, 30.09.-04.10.2013
  • "Recombinant vaccinia virus MVA expressing E and prM/M proteins of West Nile Virus.", G. Sutter, 5th European Congress of Virology, Lyon, France, 11.-14.09.2013
  • "Recombinant vaccinia MVA - a platform for development of emergency vaccines.", G. Sutter, Global Virus Network (GVN) Meeting Munich, 30.05.-01.06. 2013
  • "New Influenza vaccines: Types and modes of administration.", G. Sutter, ESWI Flu Summit  - Brussels, 02.05.2013
  • "Recombinant vaccinia MVA - a promising vaccine platform for pandemic influenza.", G. Sutter,  4th Symposium on Veterinary Sciences, ENVT, Toulouse, France, 11.-13.04.2013
  • "Vaccinia MVA vectors against emerging infections: From animal models to clinical evaluation." , G. Sutter, Robert-Koch-Institut Berlin, 09.04.2013

2012

  • "Deutsches Zentrum für Infektionsforschung (DZIF) - a new multicenter initiative in translational infection research.", G. Sutter,  National Symposium on Zoonoses Research 2012 - Berlin, 10.-12.10.2012
  • "Hazardous Orthopoxvirus infections: Pathogenesis, Prevention and Treatment.", G. Sutter, NATO Bio Warfare Defence Awareness Course - NATO SCHOOL Oberammergau, 01.-05.10.2012
  • "Vaccinia virus MVA based vector vaccines. Basic features, regulatory requests, future options.", G. Sutter, Erasmus Postgraduate School Molecular Medicine, Course in Virology 2012, Rotterdam, 07.06.2012

2011

  • "Vaccines against Vector-Borne Diseases.",  G. Sutter, 100th Anniversary NVvM & Scientific Spring Meeting 2011, Arnhem, Netherlands, 18.-20.04.2011

2010

  • "Inflammation essential to successful vaccination? Learning from poxviruses.", G. Sutter, Kloster Seeon, Bavaria / Germany, 09.-12.05.2010
  • "Modifiziertes Vacciniavirus Ankara (mVA) - ein Münchner Impfvirus auf Weltreise und zurück.", G. Sutter, Institut für Virologie, Universität Leipzig, 29.04.2010
  • "Poxvirus vaccines - immunostimulatory activities and protective capacity.", G. Sutter, Seminarvortrag MPI Magdeburg, 21.01.2010

2009

  • "Vaccinia virus MVA based vaccines - immunostimulatory capacity and protection against virus challenge.", G. Sutter, 46th OHOLO Conference, Eilat, Israel, 25.-29.10.2009
  • "Protective immunity and the sensing of viruses.", G. Sutter, Karolinska Institutet, Stockholm, 12.06.2009
  • "Poxvirus host interaction in infection and immunization.", G. Sutter, Medizinische Hochschule Hannover, Kolloquium des IRTG 1273, Twincore-Institut, Hannover, 18.05.2009
  • "Candidate Vaccines based on recombinant modified vaccinia virus Ankara (MVA).", G. Sutter, University of Helsinki, Faculty of Medicine, 08.05.2009
  • "Candidate influenza vaccines based on recombinant vaccinia virus MVA.", G. Sutter, Seminars in Experimantal Medicine. Kantonspital St. Gallen, Switzerland, 25.03.2009

Verantwortlich für den Inhalt: Wanda Schroppa